From: Art.4(1)(b) @pfizer.com>
Sent: jeudi 7 juillet 2022 17:55
To: Art.4(1)(b) (TRADE)
Subject: RE: COVID therapeutics
Attachments: Paxlovid Access Factsheet 4-1-22.pdf

Hi Art.4(1)(b),

Thanks I relayed this to EFPIA: materials are being pulled together as we speak I believe!

While not a broader landscape overview, to the extent it is of use to you, please see attached a document which provides some insights into the Pfizer therapeutic. It is still in the process of being updated to reflect some further advances in manufacturing scale up, for example manufacturing investments now also made in the US (not to mention working with contract manufacturers in Art.4(2) 1st inden and France to support increase production capacity), further companies joining the MPP agreement, as well as further access strategies.

FYI on the latter point, I would call out a few specific approaches we are taking:

- ***Multilateral Supply Agreements***: Signed agreement with **UNICEF** to supply up to 4 million treatment courses of PAXLOVID to low- and middle-income countries in 2022; Signed letter of intent with **Global Fund** for up to 6 million PAXLOVID treatment courses for supply to 130 Global-Fund eligible countries in 2022 and 2023, subject to the signing of a definitive agreement and regulatory approval or authorization.
- ***Expanding Access to Patent-Protected Medicines in Lower-Income Countries:*** Launched **An Accord for a Healthier World,** a first-of-its-kind initiative to enable sustained, equitable access to high-quality medicines and vaccines for 1.2 billion people living in lower-income countries. Pfizer has committed to provide its patent-protected medicines and vaccines available in the U.S. or European Union, including PAXLOVID, on a not-for-profit basis to 45 lower-income countries around the world and will collaborate with government and global health leaders to address barriers that limit access beyond supply, like diagnosis, education, infrastructure, storage and more.
- ***Accelerating Testing and Treatment*:** Signed a letter of intent to join **COVID Global Accountability Platform (COVID GAP)**, a joint initiative of COVID Collaborative and Duke University, along with Open Society Foundations and the Clinton Health Access Initiative (CHAI). Subject to a definitive agreement, the company will provide treatment courses of PAXLOVID, as well as funding and expert resources, to support the consortium's efforts aimed at accelerating testing and improving access to treatment in under-resourced parts of the world.
- ***Treatment Donation:*** As part of its humanitarian response, Pfizer donated 200K treatment courses of PAXLOVID to **Ukraine**.
- ***Voluntary Licensing:*** Signed a voluntary license agreement with **Medicines Patent Pool (MPP)** to enable the development and distribution of generic versions of Pfizer's oral treatment to further expand long-term global supply and access. MPP has signed sublicense agreements with 38 manufacturers, who will supply the generic versions in 95 low- and lower-middle-income countries.

I'd also flag the following link to give an overview of the R&D landscape for therapeutics, including multiple SMEs which are developing therapies and treatments. There is also a handy map to see the geographical breakdown of R&D: https://www.bio.org/policy/human-health/vaccines-biodefense/coronavirus/pipeline-tracker

I'm not sure if EFPIA have reached out to you but I understand they were planning to ask for a meeting with you and Art.4(1)(b) in the coming days.

I hope that's of some help!

Art.4(1)(b)

From: Art.4(1)(b) @ec.europa.eu>
Sent: Thursday, 7 July 2022 17:38
To: Art.4(1)(b) @pfizer.com>
Subject: [EXTERNAL] COVID therapeutics

Hi Art.4(1)(b),

When we spoke a few weeks ago, I mentioned that it would be useful to have a more complete overview on the COVID therapeutics from the side of the industry.

The discussions on this issue are already kicking off in Geneva, so it would be really useful to start with some basic facts here.

I will be speaking with EFPIA soon, so I will ask them as well. Maybe you have already heard if something is being developed by them?

Thanks!

Best regards,
Art.4(1)(b)

Art.4(1)(b)

European Commission
Directorate General Trade
Unit B3 Investment and Intellectual Property
1049 Brussels, Belgium

office: CHAR Art.4(1)(b), tel.: +32-2-2 Art.4(1)(b)
e-mail: Art.4(1)(b) @ec.europa.eu